Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer

<p>Proteins identified in RNA pulldown and mass spectrometry analysis with FZR1[m6A] or FZR1[A].</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Jiachun Su (16990970) (author)
Бусад зохиолчид:	Rui Li (16990973) (author), Ziming Chen (16990976) (author), Shaoqiu Liu (16990979) (author), Hongzhe Zhao (16990982) (author), Shuang Deng (16990985) (author), Lingxing Zeng (16990988) (author), Zilan Xu (16990991) (author), Sihan Zhao (16990994) (author), Yifan Zhou (16990997) (author), Mei Li (16991000) (author), Xiaowei He (16991003) (author), Ji Liu (16991006) (author), Chunling Xue (16991009) (author), Ruihong Bai (16991012) (author), Lisha Zhuang (16991015) (author), Quanbo Zhou (16991018) (author), Shaoping Zhang (16991021) (author), Rufu Chen (16991024) (author), Xudong Huang (16991027) (author), Dongxin Lin (16991030) (author), Jian Zheng (11732682) (author), Jialiang Zhang (16991033) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Cancer Risk Factors Molecular and Cellular Biology Therapeutic Research and Development Chemotherapy Drug Resistance Regulation of gene expression in drug resistance Epigenetics Gastrointestinal Cancers Pancreatic cancer
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
-н: Dahihm Kim (16546203)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
-н: Chong Kin Liam (15331321)
Хэвлэсэн: (2025)

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
-н: Gregory L. Beatty (15087193)
Хэвлэсэн: (2025)

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
-н: Gregory L. Beatty (15087193)
Хэвлэсэн: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
-н: Xiaohong Hong (22681698)
Хэвлэсэн: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
-н: Sanna Pikkusaari (15055802)
Хэвлэсэн: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
-н: Sanna Pikkusaari (15055802)
Хэвлэсэн: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
-н: Yufang Bao (15386826)
Хэвлэсэн: (2025)

Supplementary Table 1 from <i>N<sup>6</sup></i>-Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer
-н: Haisheng Zhang (16436982)
Хэвлэсэн: (2025)

Source Data from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
-н: Takeru Oka (15386810)
Хэвлэсэн: (2025)

Supplementary Table S1 from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
-н: Takeru Oka (15386810)
Хэвлэсэн: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
-н: Seung Yeon Oh (15051017)
Хэвлэсэн: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
-н: Nicole A. Traphagen (16677391)
Хэвлэсэн: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
-н: Nicole A. Traphagen (16677391)
Хэвлэсэн: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
-н: Alex C.H. Liu (14961921)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ocqn9h64jnga5fc993fk1eivgd